Novartis AG
NEW CRYSTALLINE FORMS OF N-(3-(2-(2-HYDROXYETHOXY)-6-MORPHOLINOPYRIDIN-4-YL)-4-METHVLPHENYL)-2 (TRIFLUOROMETHYL)ISONICOTINAMIDE AS RAF INHIBITORS FOR THE TREATMENT OF CANCER

Abstract:

The present invention relates to crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(tr- ifluoromethyl)isonicotinanmide and to processes for their preparation. Furthermore, the invention relates to a N pharmaceutical composition comprising said crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-tri- fluoromethyl)isonicotinamide, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition CA of the present invention can be used as a medicament, in particular for the treatment of cancers.